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Chronic secondary mitral regurgitation (SMR) is a com-plex entity that is often clinically underappreciated.1 It 
complicates either ischemic heart disease or dilated cardio-
myopathy; its prevalence varies among series but may reach 
≤50% in patients with heart failure.2 When present, SMR 
may exhibit a broad range of severity and confers an adverse 
prognosis, which is worse with increasing severity of mitral 
regurgitation (MR).3,4 The management of SMR poses a 
unique set of challenges, based partly on the complexity of the 
valve disorder and the still-evolving adoption of the optimal 
therapeutic approach.5 Noninvasive imaging and, in particu-
lar, echocardiography, plays a critical role for the initial and 
longitudinal assessment, for individual risk stratification and 
outcome prediction, and for guiding intervention in patients 
with chronic SMR.6
Cause, Mechanisms, and Structural 
Remodeling
SMR develops because of a combination of mitral leaflet teth-
ering secondary to left ventricular (LV) dilatation/deformation 
with papillary displacement/discoordination, annular dilata-
tion/dysfunction, insufficient LV-generated closing forces 
attributable to reduction of LV contractility, and global LV/
papillary muscle dyssynchrony.1,5 Tethering of the mitral leaf-
lets is the principal lesion of SMR and results in restriction of 
systolic leaflet motion, namely type IIIb of Carpentier’s classi-
fication. SMR does not typically occur in global LV dysfunc-
tion without tethering. However, once tethering occurs, leaflet 
closure is further impaired by LV dysfunction because there is 
decreased force opposing tethering.6–9
The key event in the pathogenesis of SMR is the distortion 
of normal LV geometry—regional and global LV remodel-
ing—with subsequent apical and lateral displacement of pap-
illary muscles, which, in turn, draws the chordae tendineae 
away from the line of coaptation.7,8 The extent of LV systolic 
dysfunction and dilatation is weakly correlated to the degree 
of SMR unless accompanied by geometric distortion in the 
region of the papillary muscles.1,9 With progressive global/
regional LV remodeling, the geometric distortion in the region 
of papillary muscles insertion increases and the SMR is wors-
ened. However, in ischemic cardiomyopathy, SMR may be 
mitigated by papillary muscle elongation/remodeling via a 
reduction in leaflet tethering forces.10 Regional mechanical LV 
dyssynchrony especially that involves the papillary muscles 
can promote SMR through a reduction in the systolic contrac-
tion of the posterior mitral annulus.11 Global LV dyssynchrony 
contributes to SMR through a blunted LV systolic pressure 
rise resulting in decreased closing forces and leaving the leaf-
let deforming tethering forces relatively unopposed.12,13
The morphological hallmark in SMR is the deformation 
of the mitral valve7 the extent of which is the major deter-
minant of the degree of SMR.14,15 The retracted chordae 
tendineae secondary to LV remodeling and displacement of 
papillary muscles tether the valve leaflets, preventing normal 
valve closure and resulting in valvular incompetence. The 
tethering shape varies according to the site and extent of LV 
remodeling.16 In asymmetrical tethering, the tenting typically 
predominates in the region of the posterior-medial scallop of 
the posterior leaflet (P3) because of apically and posteriorly 
displaced posterior papillary muscle secondary to localized 
LV remodeling12 (Figure 1). Tethering of secondary chords 
contributes to development of a hockey-stick deformity of the 
anterior leaflet.7 As a result, the coaptation point of the leaf-
lets is displaced posteriorly with respect to the center of the 
LV cavity. The consequence is anterior leaflet over-ride with 
a posterior SMR jet. In symmetrical tethering, the coaptation 
point of the mitral valve is moved apically, with a large tent-
ing and both leaflets are involved to a similar degree, causing 
a central regurgitant jet. Tethering is thus higher in patients 
with global LV remodeling16,17 (Figure 2). Alterations in mitral 
annulus size and shape contribute to the development of SMR 
as an adjunctive mechanism18 (Figure 3). In fact, patients with 
isolated mitral annular dilation in the absence of ventricular 
abnormalities show less MR than those with dilated cardio-
myopathy, even after correction for annulus size.19 The normal 
mitral leaflet area is more than double the area of the annulus, 
indicating a significant reserve before annular enlargement 
can lead to noncoaptation. Annular dilatation is not limited to 
anterior–posterior region but extends to intertrigonal zone and 
results in loss of the typical saddle shape of the annulus, which 
reduces leaflet curvature and thereby increases leaflet stress.16 
Alterations in annular contraction also interfere with leaflet 
coaptation and contribute to SMR. Severe asymmetrical LV 
remodeling in the basal inferoposterior LV and the consequent 
asymmetrical annular dilatation particularly exacerbate SMR 
because of less reduction in annular size during systole.5
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In addition, mitral valve leaflets undergo progressive 
remodeling with elongation, stiffening, increase in matrix 
thickness, and fibrosis in response to the stresses imposed 
by increased leaflet tethering and mitral annular dilata-
tion.20–22 The extent of this remodeling differs in individual 
patients and for a similar degree of mitral leaflet tethering 
and LV remodeling, suggesting that leaflet enlargement is 
not attributable to a straightforward passive adaptation to 
leaflet stretch. In SMR, mitral leaflet area may increase 
by ≤35% on average.21 However, such an adaptation is 
Figure 1. Assessment of mitral valvular deformation and global and regional left ventricular remodeling in patients with secondary mitral 
regurgitation. A, Symmetrical tenting pattern. B, Asymmetrical tenting pattern. C, Measurements of the tenting area (TA), coaptation dis-
tance (CD), and posterolateral angle (PLA). D, Measurements of the sphericity index (D1), interpapillary muscle distance (IPMD; D2), and 
apical displacement of the posteromedial papillary muscle (D3). PLL indicates posterior leaflet length; and SI, sphericity index.
Figure 2. Patients with secondary mitral regurgitation. A to D, Symmetrical tenting pattern. E to H, Asymmetrical tenting pattern. A and 
E, Two-dimensional parasternal long-axis view. B and F, Three-dimensional volume rendering of the mitral valve. AML indicates anterior 
mitral leaflet; and PML, posterior mitral leaflet. C and G, Color flow of the regurgitant jet. D and H, Three-dimensional reconstruction of 
the tenting region. Arrow indicates zone of regurgitation.
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often insufficient to meet the need for increased leaflet 
area imposed by the change in mitral valve configura-
tion. Therefore, the discrepancy in leaflet area in relation 
to the required closure area (leaflet area/closure area) is an 
important determinant of the degree of MR.22 Interestingly, 
although valve enlargement can promote mitral coaptation, 
it can be a counterproductive by inducing maladaptive valve 
thickening, stiffness, and fibrosis.
Role of Imaging
Two-dimensional (2D) transthoracic and transesophageal 
echocardiography (TEE) play a substantial role in the evalua-
tion of SMR.3 However, 3D echocardiography (3DE) has con-
tributed most to the understanding of the structural remodeling 
that accompanies SMR.16–18 Three-dimensional echocardiogra-
phy has demonstrated superiority over 2DE in measuring LV 
volumes, localizing and assessing the extent of mitral valve 
deformation, and determining the shape of the regurgitant ori-
fice.11 In patients with inadequate images or discrepant find-
ings by echocardiography, cardiac magnetic resonance (CMR) 
can be used to quantify MR severity, evaluate LV anatomy and 
function, and assess the presence and extent of myocardial scar 
(late enhancement).23 Cardiac computed tomography is rarely 
indicated in the evaluation of SMR, even if the extent of mitral 
valve deformation and MR severity might be assessed.24 Cardiac 
computed tomography could be however useful in some cases 
to evaluate the coronary anatomy (ie, limited vascular access; 
Figure 4). Irrespective of imaging technique, the assessment 
of SMR needs to address findings related to mitral valve con-
figuration, the severity of SMR, and LV remodeling because 
these features govern the indications for intervention and 
clinical outcomes.5,7
Evaluation of Mitral Valve Configuration
The evaluation of mitral valve configuration should also 
include consideration of the MR jet direction.3,5 A posterior-
directed jet (P2–P3) is usually associated with eccentric valve 
involvement and point of coaptation (asymmetrical tethering), 
whereas a central jet marks symmetrical involvement and 
point of coaptation (symmetrical tethering). Despite no evi-
dence of structural mitral valve disease, the displacement of 
the leaflets into the LV leads to several morphological changes 
that can quantify the global and regional tethering burden.5 
Annular dimensions, tenting area (region enclosed between 
the annulus and the mitral valve leaflets body), anterior and 
posterior leaflet angles, tenting height (vertical distance 
between the mitral annulus and the leaflet coaptation point), 
bending distances, and coaptation length/surface (a measure 
of coaptation reserve) are the commonest parameters mea-
sured.11 With 2D echo, tethering is best appreciated in apical 
4-chamber view but can be obtained from the parasternal long-
axis view.9 With CMR, mitral valve anatomy is best imaged 
by acquisition of standard short-axis, 2-, 3-, and 4-chamber 
long-axis views in combination with oblique long-axis cines 
orthogonal to the line of coaptation.23 However, the assess-
ment of the exact location of the maximum tenting zone with 
2D echo or CMR may be imprecise. Measures of mitral valve 
configuration parameters are now readily available using 3DE, 
which reduces the risk of foreshortened views and off-axis 
planes. Three-dimensional tenting volume correlates better 
with effective regurgitant orifice area (EROA) in patients with 
SMR.12 Three-dimensional echocardiography also represents 
the method of choice to provide accurate evaluation of leaflets 
remodeling and mitral annulus dimensions and dynamics.25,26 
For instance, the leaflet area/closure area and leaflet area/
Figure 3. Three-dimensional (3D) reconstruction of the mitral annulus in secondary mitral regurgitation with measurements of the antero-
posterior (A) and intercommissural (B) diameters, anterior (C) and posterior (D) leaflet surfaces, and dynamics of the mitral annulus (E). 
E, Dynamic motion analysis of the mitral annulus during the cardiac cycle. F, Schematic 3D representation of the mitral annulus, which 
appears flat, deformed, and no longer saddle shaped. A indicates anterior; AL, antero-lateral commissure; AO, aorta; P, posterior; and 
PM, papillary muscle.
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annular area ratios and the 3D-derived indexes of coaptation 
are lower in patients with significant SMR.24 However, it is not 
clear whether these 3D echo measurements provide incremen-
tal information to standard 2D echo measures for predicting 
outcome after treatment (Table 1).
Evaluation of LV Remodeling/Function
The location and extent of LV abnormalities/remodeling 
should be evaluated. The following findings are reported: LV 
volumes and shape (sphericity index), regional wall motion 
abnormalities, and markers of transmural necrosis (hyperecho-
genic segments, diastolic thickness <5.5 mm, severe reduction 
in segmental strain, no contractile reserve, >50% late gado-
linium enhancement [LGE]).2–6 LV ejection fraction and sphe-
ricity index (actual 3D volume compared with the volume of 
a sphere whose diameter is derived from the major LV long 
axis) are obtained preferably using 3D echo. When 3D is not 
available, the 2D biplane Simpson rule is recommended. With 
CMR, the LV dimensions are derived from a series of multisec-
tion perpendicular to the long axis of the LV (10–12 contigu-
ous slices in short-axis direction). Regardless of the method 
used, because it is highly dependent on loading conditions, 
LV ejection fraction often overestimates the systolic function 
in case of significant SMR. Measurement of LV maximal dP/
dt using continuous-wave Doppler of SMR jet can provide 
noninvasive estimation of global mitral closing forces.21 The 
parameters to be used to quantify LV dyssynchrony are con-
troversial. Regional remodeling is quantified by the posterior 
and lateral displacements of 1 or both papillary muscles. Two-
dimensional echo and CMR measurements include interpapil-
lary muscle distance and posterior papillary–fibrosa distance. 
With 3D echo, the extent of papillary muscles displacement 
can be better evaluated. A specific advantage of CMR lies on 
the possibility to assess the presence and extent of myocardial 
fibrosis, which can be either diffuse (quantification of myocar-
dial extracellular expansion based on T1-mapping sequence) 
or focal (LGE). The more extensive the scar burden/focal 
fibrosis (LGE-CMR), the lower the likelihood of LV reverse 
remodeling after revascularization27 or cardiac resynchroniza-
tion therapy.28 Cardiac computed tomography vein assessment 
in combination with LGE-CMR might be considered as rea-
sonable options among other imaging tests (ie, invasive venous 
angiography, stress echocardiography, nuclear imaging) in 
patients thought to have extensive necrosis (Figure 5). The 
added value of T1-mapping to conventional LGE-CMR evalu-
ation in patients with SMR still needs to be evaluated.
Assessment of Severity of MR
Echocardiographic assessment of the severity of SMR relies 
on an integrated approach using qualitative, semiquantitative, 
and quantitative parameters. A challenge in the evaluation of 
the degree of SMR is the temporal variation both within sys-
tole of a single cardiac cycle and during interval follow-up 
imaging related to loading conditions and changes in LV size.
Current Methods and Limitations
A combination of 2DE, spectral, and color Doppler parameters 
form the standard approach to quantify the degree of SMR.3,29 
Despite the influence of settings, hemodynamic conditions, 
and mechanism of MR, the presence of a central color jet with 
a jet area <4 cm2 or a jet that measures <10% (MR jet/left 
atrial area) is highly suggestive of mild SMR. On the contrary, 
large central MR jets reaching left atrial roof and pulmonary 
veins (with or without systolic spectral Doppler flow reversal) 
suggest significant MR. The vena contracta (VC) width in the 
parasternal long-axis view is another measure of the sever-
ity with a cutoff of ≥0.4 cm indicative of severe SMR.30 It is 
should be noted that although VC is relatively independent 
Figure 4. Patient with a history of anterior myocar-
dial infarction, secondary mitral regurgitation, and 
severe left ventricular remodeling. Three-dimen-
sional cardiac computed tomography showing a 
significant left anterior descending artery stenosis 
(A and B, white arrows). Cardiac magnetic reso-
nance demonstrating the presence of significant 
mitral valve deformation, with a severe tenting 
(black arrows) and a large zone of myocardial scar 
(orange arrows; C and D).
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of the driving pressure and flow rate, it is influenced by the 
dynamic variations in orifice area, which occurs with SMR. 
Calculation of EROA using the surface area of the proximal 
flow convergence (PFCR) is another approach to quantify 
SMR. The PFCR is imaged in the apical 4-chamber or api-
cal long-axis view with appropriate settings, and the radius 
of the largest flow convergence in either view is used to mea-
sure the EROA using the standard formula assuming a hemi-
spheric flow convergence. A cutoff EROA of ≥0.20 cm2 is 
recommended for grading SMR as severe.3 Dynamic changes 
in MR, the predominant noncircular regular orifice shape, 
and constrained PFCR in the setting of regional myocardial 
deformity and leaflet tethering can limit the use and accuracy 
of the PFCR-based EROA computation in SMR. Regurgitant 
volume and fraction (RV/regurgitant fraction) in SMR is a 
valuable index of severity, but it is not routinely done by 2D 
echo/Doppler because of the need for cumbersome manual 
measurements in which small errors result in significant inac-
curacies. Furthermore, individual measurements are made in 
disparate cardiac cycles, which introduce further errors. An 
RV of ≥30 mL signifies severe SMR (Figure 6).
Newer Methods and Approaches
Recent advances in real-time 3D B-mode and color-flow Dop-
pler (CFD) echocardiography have been valuable in mak-
ing this technology more practical for routine clinical use.31 
Furthermore, CMR may prove to be a good alternative and 
complementary to echocardiography in selective instances. 
Three-dimensional B-mode TEE and CMR studies show that 
the anatomic regurgitant orifice tend to track along the leaf-
let coaptation plane and have an elliptical, irregular, or linear 
shape in vast majority of patients with SMR.32 Manual pla-
nimetry of the orifice area yields anatomic regurgitant orifice 
area, which is an important adjunct to flow-based measures of 
EROA. The anatomic regurgitant orifice area closely tracks 
the color Doppler–based VC area.33 The latter can be now 
obtained from 3D color Doppler imaging by both transtho-
racic echocardiography and TEE. A VC area of ≥0.41 cm2 
seems to be indicative of severe MR although further valida-
tion of this cutoff is necessary given that the comparison stan-
dard in most has been conventional 2D estimates of severity 
of MR. Also, the cutoff value for what constitutes severe SMR 
may be lower than in degenerative MR.34 Despite these limita-
tions, VC area is probably more accurate than VC width by 
2D in SMR.35,36 Imaging the PFCR with 3D CFD has empha-
sized the considerable limitations of 2D-based computation of 
EROA. Several studies have confirmed that 3D is superior to 
2D in more accurately characterizing the shape and the sur-
face area of the PFCR in SMR. A more recent advancement 
in which the 3D surface area of the PFCR can be automati-
cally measured and integrated during the duration of systole 
allows computation of a peak 3D EROA and integrated 3D RV 
by real-time volume CFD imaging. The latter has been spe-
cifically shown to be accurate when compared with CMR RV 
in SMR, although further confirmation of this is required in 
larger numbers and in multiple centers.37 The intrinsic limita-
tions of angle dependency of velocity profiles of the PFCR in 
relation to transducer location still apply to 3D CFD imaging, 
but it is more accurate than 2D in characterizing the shape, and 
automation makes it attractive for routine clinical application.
Another approach using real-time 3D volume CFD imaging is 
to measure mitral and LV outflow tract stroke volume and com-
pute RV. The individual stroke volume can be measured auto-
matically by integrating the volume color Doppler data and the 
area of the mitral annulus and LV outflow tract simultaneously 
through the cardiac cycle. This automated approach has been 
shown to be both more accurate and reproducible than using the 
spectral Doppler velocity profiles and 2D areas.38 Furthermore, 
when extended specially to SMR, the RV/regurgitant fraction 
(regurgitant fraction) computed by this automated 3D CFD 
imaging compares well to CMR.37 This promising single-center 
experience will need additional validation in a larger popula-
tion. The presence of high-velocity aliasing in the LV outflow 
tract can limit the accuracy and the application of this technique 
just as the presence of multivalve disease. However, it does pro-
vide a solution in the presence of multiple MR jets, when VC 
and PFCR methods are not valid or reliable or to evaluate the 
residual MR through a dual orifice after MitraClip intervention.
Table 1.  Two- and Three-Dimensional–Derived 
Echocardiographic Parameters Obtainable in SMR
Mitral Parameters 2D TEE 3D TEE
Annulus
  Intercommissural distance + ++
  Septolateral distance + ++
  Perimeter + ++
  Annulus height − ++
  Annulus dynamics − ++
Leaflets
  Anterior leaflet area − ++
  Posterior leaflet area − ++
Leaflet angle
  Posterior leaflet angle + ++
  Anterior leaflet angle + ++
Coaptation
  Coaptation depth + ++
  Coaptation indexes − ++
  Leaflet coaptation area − ++
Tethering
  Tenting area + +
  Tenting volume − ++
Ventricle
  LV end-diastolic volume + ++
  LV end-systolic volume + ++
  LV dyssynchrony (global/PMs) + ++
Interpapillary distance
  PM tip + ++
  PM body + ++
SMR evaluation
  PISA shape + ++
  Regurgitant orifice geometry + ++
2D indicates 2-dimensional; LV, left ventricular; PM, papillary muscle; PISA, 
proximal isovelocity surface area; SMR, secondary mitral regurgitation; and TEE, 
transesophageal echocardiography.
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CMR is a valuable adjunct to echocardiography in the eval-
uation of SMR (Figure 7).39 When 2DE/3DE is available and 
optimal, the incremental role of CMR is limited with respect 
to grading severity of SMR. It is arguably superior to any 
echocardiographic approaches for the measurement of RV/
regurgitant fraction. Similarly, accurate measurement of LV 
volume/size as an index of severity of MR may be potentially 
more accurate with CMR although 3DE is proving to be as 
good a technique and more practical. Although VC width, VC 
area, and anatomic regurgitant orifice area can be assessed by 
CMR,40 it is only necessary when a combination of transtho-
racic echocardiography and TEE does not provide the infor-
mation or there is discrepant information. The presence of 
atrial fibrillation in up to a third of patients with SMR further 
limits the use of CMR. The potential real strength of routine 
CMR in SMR may be in the assessment of the LV myocardial 
scar burden and perhaps mechanical function, which may pre-
dict clinical outcomes and success of interventions for SMR.
Imaging Interventions
Although interventions to treat SMR remain unsatisfactory 
with respect to survival benefit,41,42 there is evidence that reduc-
ing or abolishing SMR improves symptoms and attenuates pro-
gressive adverse LV remodeling.43,44 Interventional approaches 
have mainly focused on the mitral valve, and although various 
subvalvular techniques have been explored, there is no consen-
sus on which of these are optimal. Recent advances in device-
based therapies have further expanded the options in SMR, all 
of which have refocused the role of imaging in the selection, 
guidance, and postprocedural assessment.45
Surgical Approaches
The predominant surgical technique is restrictive annuloplasty 
usually in the setting of coronary artery bypass grafting and 
in the presence of at least moderate SMR. The role of TEE 
in restrictive annuloplasty is primarily to quantify the degree 
of MR and to quantify extent of mitral valve tethering. The 
presence of significant tethering does not preclude annulo-
plasty, but it seems to be predictive of residual and recurrent 
MR46 (Table 2). Whether novel 3D parameters of mitral valve 
geometry (mitral leaflet size, annulus surface/area, coapta-
tion indexes) by delineating the mechanisms associated with 
failure of annuloplasty improve the selection of patients and 
minimize procedural failure remains to be demonstrated. 
Similarly, whether the extent of preoperative LV remodel-
ing is predictive of recurrent MR is still an ongoing question. 
Annuloplasty is performed with rings, which are specifically 
designed to accommodate the mitral annulus distortion (IMR 
ETlogix and GeoForm rings, Edwards Lifesciences, CA) 
without replicating the normal mitral annulus. Sizing the ring 
can be guided by intraoperative TEE. Figure 8 illustrates an 
example of how this can be done using intraoperative 3D TEE. 
The role of imaging in subvalvular approaches such as second-
ary chord cutting and repositioning of the papillary muscles is 
evolving, but preliminary reports of 3D modeling of papillary 
muscles and chords to aid interventions are encouraging and 
may help to reduce postoperative recurrence of MR.47 When 
ventricular plication techniques are used, imaging may be a 
valuable aid to assess ventricular shape and size.
Device-Based Approaches
Cardiac resynchronization therapy9–14 and percutaneous mitral 
valve repair techniques48 can decrease MR in selected groups 
of patients eligible for these treatments. Furthermore, there is 
also evidence for combined device approach or surgical–device 
approach to maximize the benefits of interventions in SMR.49 
Recent studies have applied stringent and varied inclusion cri-
teria for device implantation and therefore have potentially 
excluded a substantial number of patients who might have ben-
efited from these approaches and have included degenerative 
Figure 5. Cardiac computed tomography (CT) vein 
assessment in combination with late gadolinium 
enhancement (LGE-cardiac magnetic resonance 
[CMR]) in a patient with subendocardial infero-
posterolateral myocardial infarction. PV indicates 
posterior vein.
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and SMR in 1 cohort applying the same cutoff for severity of 
MR.50 Moreover, the disparate approach to defining imaging 
response to these device based may impede progress in this 
field. Thus, there is an urgent need to standardize selection of 
patients, guidance and assessment of procedural success, and 
definition of response versus nonresponse, especially with the 
ongoing Clinical Outcomes Assessment of the MitraClip Per-
cutaneous Therapy for Extremely High-Surgical-Risk Patients 
(COAPT) and Randomized Study of the MitraClip Device In 
Heart Failure Patients with Clinically Significant Functional 
Mitral Regurgitation (RESHAPE-HF) studies, which are 
focused on application of MitraClip to patients with SMR.
Unresolved Issues in Imaging Response  
to Treatment
Imaging can assess absence of MR after annuloplasty or 
replacement with accuracy, but evaluation of reduction of 
MR is more challenging especially when the postprocedural 
Figure 6. An illustrative example of secondary mitral regurgitation (SMR; A and B) in which 2-dimensional (2D) VCW (C) is consistent with 
moderate mitral regurgitation (MR). D, Measurement of the velocity time integral and peak velocity of the MR regurgitant jet using continu-
ous wave Doppler. The 2D proximal flow convergence (PFCR)–based effective regurgitant orifice area (EROA) in the apical 4-chamber and 
apical long-axis views (E and F) is 0.15 cm indicative of less than severe MR. Automated 3D surface area modeling by real-time 3D volume 
color-flow Doppler imaging (arrows in G and I) shows elliptical/noncircular orifice shape. Using the 3D surface area to compute the 3D 
PFCR-based EROA yields an orifice size of 0.33 cm2 consistent with severe SMR. H, Data automatically calculated by the software. PISA 
indicates proximal isovelocity surface area; RF, regurgitant fraction; VCW, vena contracta width; and VTI, velocity time integral.
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anatomy is unusual such as the double orifice after MitraClip 
implantation (Figure 9).44 It is best to use the same integrative 
assessment to quantify residual MR as the one that is recom-
mended for quantification of native SMR. The added value 
of 3D echocardiographic assessment of residual MR severity 
is unknown, but intuitively this would make sense, and data 
from ongoing prospective studies will help to ascertain this. 
At the present time, the definition of success of those proce-
dures, which primarily reduce MR, remains unclear. The cur-
rent imperfect practice in which an acceptable reduction in 
SMR is defined as a decrease by 1 grade in severity is perhaps 
the most practical. In the acute stage, an increase in forward 
stroke volume (>10%–15%) may also be a marker of good 
response to treatment. However, whether these responses 
necessarily translate into chronic improvement of cardiac 
performance is unknown. Similarly, a positive LV remodel-
ing process after cardiac resynchronization therapy is defined 
as reduction in LV end-systolic volume (>10%–15%).51 How-
ever, the level to which the reduction in MR plays a role in 
reverse LV remodeling remains unclear and requires to be 
evaluated prospectively. It may be also possible to better select 
patients and predict response in the future based on accumu-
lated postprocedural imaging data on the degree of reduction 
in MR, positive LV remodeling, and clinical outcomes.52
Imaging to Predict Progression and  
Clinical Outcomes
Disease progression in SMR is a complex interplay between 
LV remodeling which predates MR and the latter which can 
initiate and promote LV remodeling1–6 through increased 
wall stress and activation of neurohumoral mechanisms.20–22 
SMR is fundamentally a ventricular disease; hence, the 
remodeling of the LV, the left atrium, and the mitral annu-
lus are main determinants for predicting the progression of 
MR.53 However, SMR begets progressive SMR as shown 
by Enriquez-Sarano et al53 who reported an average yearly 
increase in RV of 1.5±9 mL and 0±5 mm2 in EROA in a 
small group of patients (n=10). In addition, the presence of 
Figure 7. An illustrative example of secondary mitral regurgitation (SMR; A and B) in which 3-dimensional (3D) vena contracta area (VCA; 
A) by real-time volume color-flow Doppler (CFD) transthoracic echocardiography is 0.50 cm2, consistent with severe mitral regurgitation 
(MR). The automated 3D proximal flow convergence (PFCR) modeling (B) shows a slit-like orifice shape, and using the 3D surface area 
yields an effective regurgitant orifice area (EROA) of 0.53 cm consistent with the assessment by VCA of severe SMR. Automated mitral 
and aortic stroke volume (SV) measurement by real-time 3D volume CFD imaging (C, yellow and cyan blue disks track the mitral annulus 
and the left outflow tract [LVOT], respectively; the green mesh shows automated tracking of LV endocardial surface) yields a regurgitant 
volume (RV) of 61.2 mL. Measurement of aortic and total LV SV by cardiac magnetic resonance (CMR; D) shows an RV of 64.3 mL, com-
parable to RV by 3D CFD imaging. MV indicates mitral valve; PISA, proximal isovelocity surface area; and VTI, velocity time integral. 
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dynamic changes in in the degree of SMR can accentuate the 
vicious cycle.54
The presence and degree of SMR is associated with a 2-fold 
increase in mortality (38±5% versus 61±6%; P<0.001) after 
myocardial infarction,55 with increased mortality even in the 
presence of mild MR.53 In patients with ischemic congestive 
heart failure and minimal or no symptoms56 and in those with 
New York Heart Association II and III class,57–59 the pres-
ence of SMR, and especially in those with EROA ≥20 mm2, 
mortality and morbidity was increased. Rossi et al44 recently 
emphasized in a large multicenter study the importance of 
quantifying SMR to predict all-cause mortality or hospitaliza-
tion for worsening of heart failure. Interestingly, their cohort 
included >400 patients with ischemic dilated cardiomyopathy. 
Even in idiopathic dilated cardiomyopathy,44 severe SMR, 
defined as RV >30 mL or EROA ≥20 mm2 or VC >0.4 cm, was 
associated with a 2-fold increased risk of adverse events after 
adjustment for LV ejection fraction and diastolic function. 
In a retrospective analysis of 2242 patients, the presence of 
moderate MR or even mild MR at the time of coronary artery 
bypass grafting was associated with lower 5-year postopera-
tive survival as compared with patients without SMR (70±1%, 
84±1%, and 86±1% for patients with moderate, mild, or no 
MR, respectively), even after adjustment for the degree of LV 
dysfunction and other comorbidities.58 SMR is often dynamic 
with intermittent changes related to changes in loading con-
ditions. An increase in EROA by ≥13 mm2 during exercise 
is associated with reduced event-free survival, higher risk of 
heart failure, and major cardiac events compared with patients 
with no or mild increase or with decrease in MR severity.58–60
Despite all this, debates still exist about whether SMR is 
only a marker of poor LV function or an independent risk fac-
tor for adverse outcome. Indeed, the severity of SMR tends to 
follow the severity of LV dysfunction causing SMR. Moreover, 
Table 2. Preoperative Echocardiographic Parameters to Predict 
Annuloplasty Failure (Persistence and Recurrence of MR)
Parameter TTE/TEE Cutoff Value
Sensitivity/ 
Specificity, %
Mitral annulus diameter TEE ≥37 mm 84/76
Tenting area TTE ≥2.5 cm2 64/95
Tenting area TEE ≥1.6 cm2 80/54
Coaptation distance TTE ≥10 mm 64/90
Coaptation distance TEE ≥10 mm NA
Posterior leaflet angle TTE ≥45° 100/95
Posterior leaflet tethering  
distance
TTE ≥40 mm NA
Distal mitral anterior  
leaflet angle
TTE >25° 88/94
Anterior mitral leaflet  
tethering angle
TTE ≥39.5° NA
MR grade TEE ≥3.5 42/81
MR jet TTE Central or complex NA
LV end-systolic volume TTE ≥145 mL 90/90
Systolic sphericity index TTE ≥0.7 100/100
Wall motion score index TTE ≥1.5 80/82
Interpapillary muscle distance TTE >20 mm 96/97
LV indicates left ventricular; MR, mitral regurgitation; NA, not available; TEE, 
transesophageal echocardiography; and TTE, transthoracic echocardiography.
Figure 8. Three-dimensional (3D) transesophageal echocardiography (TEE) to guide mitral valve annuloplasty in secondary mitral regurgita-
tion (SMR). Real-time 3D TEE shows the typical regurgitant orifice in SMR associated with posterior leaflet tethering (red arrows in A) and 
a single torn chord at P2 (black arrow in A) and the corresponding intraoperative findings (red and black arrows in B). Automated 3D TEE 
quantitative modeling also shows the regurgitant orifice (C) consequent to tethering (red arrows) and prolapse of P2 (black arrow). The 
extent of tethering is shown in blue hues in D. The 3D intercommissural distance can be automatically measured (red dotted line in E), the 
anterior leaflet height (pink line in E) can also be sized to guide selection of ring size, and the heights of the scallops of the posterior leaflet 
can also be sized (last figure in E). A Physio ring (30 mm, 1 size less than that predicted by the intercommissural distance/anterior leaflet 
height) was used for restrictive annuloplasty (F).
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correcting SMR does not prolong life, which would be expected 
to occur if MR affected the outcome.41,42 Currently, no outcome 
studies using contemporary imaging techniques to quantify MR 
and evaluate LV function/remodeling have been conducted to 
address this dilemma. In this regard, large-scale studies examin-
ing the added value of 3DE and CMR are needed.
Future Directions
Better understanding of the origin and evolution of SMR is 
necessary to enable building more effective therapeutic strate-
gies of this complex valvular disease. Detailed mapping of the 
geometric substrates promoting SMR will likely allow devel-
oping tailor-made innovative technical approaches targeted 
toward specific mechanisms. Advances in diagnostic imaging 
techniques will continue to play a major role in the assess-
ment of SMR. Our role as imagers will be to identify the best 
imaging modalities in individual patients. The Progressions 
and Outcome of Secondary Mitral Regurgitation (POMAR) 
study has been specifically designed to address this question 
by comparing real-time 3D color transthoracic echocardiogra-
phy and CMR imaging for the assessment of MR severity and 
LV remodeling.
Conclusions
A comprehensive evaluation of SMR includes the quantitative 
description of the structural changes in the LV and the mitral 
valve apparatus and the severity of MR predominantly using 
a combination of echocardiography and, if needed, of CMR. 
Whether newer techniques and technologies enhance the assess-
ment of SMR and improve our ability to predict progression, 
outcomes, and guidance of therapy remains to be seen. Large 
multicenter studies that incorporate these newer approaches to 
image SMR may help to fill the current gaps in knowledge.
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